Table 2.
Distribution and average annual rates of invasive cancer by treatment group and tumor characteristics in the NSABP STAR trial.
| Pathological characteristic |
Events (n, %)* |
Rate per 1000 individuals |
Risk ratio§ | 95% confidence interval |
|||
|---|---|---|---|---|---|---|---|
| Tamoxifen | Raloxifene | Tamoxifen | Raloxifene | Difference‡ | |||
| Tumor size (cm) | |||||||
| ≤1.0 | 47 (29.7) | 62 (37.6) | 1.24 | 1.63 | −0.39 | 1.31 | 0.88–1.96 |
| 1.1–3.0 | 96 (60.8) | 91 (55.2) | 2.53 | 2.39 | 0.14 | 0.94 | 0.70–1.27 |
| ≥3.1 | 15 (9.5) | 13 (7.8) | 0.40 | 0.34 | 0.06 | 0.86 | 0.38–1.94 |
| Unknown | 5 | 2 | 0.13 | 0.05 | 0.08 | 0.40 | 0.04–2.43 |
| Nodal status | |||||||
| Negative | 117 (75.5) | 132 (80.5) | 3.09 | 3.49 | −0.37 | 1.13 | 0.87–1.46 |
| Positive | 38 (24.5) | 32 (19.5) | 1.00 | 0.84 | 0.16 | 0.84 | 0.51–1.38 |
| Unknown | 8 | 3 | 0.21 | 0.08 | 0.13 | 0.37 | 0.06–1.55 |
| Estrogen receptor status | |||||||
| Negative | 44 (27.7) | 51 (32.1) | 1.16 | 1.34 | −0.18 | 1.15 | 0.75–1.77 |
| Positive | 115 (72.3) | 108 (67.9) | 3.04 | 2.86 | 0.18 | 0.94 | 0.71–1.24 |
| Unknown | 4 | 8 | 0.11 | 0.21 | −0.10 | 1.99 | 0.53–9.02 |
*
Percentage of women with known information.
‡
Rate in the tamoxifen group minus rate in the raloxifene group.
§
Risk ratio for women in the raloxifene group compared with women in the tamoxifen group.
NSABP: National Surgical Adjuvant Breast and Bowel Project; STAR: Study of Tamoxifen and Raloxifene.